文献速递心力衰竭与心肌病

影像衍生肌少性肥胖指数与心血管结局及心力衰竭风险

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.
PubMed 文献 · J Am Coll Cardiol · 2026-07-01

该研究基于 55768 例心血管磁共振检查开发深度学习流程,量化胸大肌质量并结合体重构建肌少性肥胖指数。较高指数与不良心脏重构、心力衰竭、心血管死亡及全因死亡风险升高相关。遗传和转录组分析提示该表型具有临床意义,并指向 ACVR2B 等潜在治疗靶点。

要点

  • 肌少性肥胖指数升高与心力衰竭、心血管死亡和全因死亡风险增加相关。
  • 该指数可基于心血管磁共振和体重进行转化应用评估。
  • ACVR2B 是潜在治疗靶点,相关药物正与司美格鲁肽联合测试。

核心结论

  • 肌少性肥胖是具临床意义的心血管风险表型,并指向可行的治疗靶点。

研究设计与样本

  • 研究开发深度学习流程,从 55768 例心血管磁共振检查中量化胸大肌质量。
  • 结合体重构建肌少性肥胖指数,并用多变量模型检验其与心脏重构及不良结局的关联。
  • 研究整合长期随访、全基因组关联分析、共定位、多基因风险评分及骨骼肌转录组分析。

主要发现

  • 肌少性肥胖指数较高与不良心脏重构相关。
  • 指数较高与新发心力衰竭风险升高相关(HR:1.31;95% CI:1.16-1.49)。
  • 指数较高与心血管死亡风险升高相关(HR:1.51;95% CI:1.25-1.81)。
  • 指数较高与全因死亡风险升高相关(HR:1.37;95% CI:1.26-1.49)。
  • 全基因组关联分析识别出 16 个肌少性肥胖相关位点。

关键数值与推荐

  • 肌少性肥胖指数由胸大肌质量(心血管磁共振量化)与体重结合计算。
  • 新发心力衰竭:HR:1.31;95% CI:1.16-1.49。
  • 心血管死亡:HR:1.51;95% CI:1.25-1.81。
  • 全因死亡:HR:1.37;95% CI:1.26-1.49。
  • 全基因组关联分析识别出 16 个相关位点。

临床怎么用

  • 可考虑利用心血管磁共振胸大肌质量结合体重评估肌少性肥胖指数以辅助心血管风险分层。
  • 对肌少性肥胖表型患者,未来可关注以 ACVR2B 为靶点的干预策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic value of obesity in cardiovascular disease is complex. Measures such as body mass index and waist-to-height ratio show differing associations with outcomes, especially in heart failure. Assessing sarcopenic obesity, the coexistence of excess fat and low muscle mass, may clarify this relationship; however, quantifying sarcopenia in clinical practice remains challenging. OBJECTIVES: The goal was to establish a translatable method of assessing sarcopenic obesity from cardiovascular imaging and assess its clinical relevance using long-term follow-up, genomic, and transcriptomic data. METHODS: We developed a deep learning pipeline to quantify pectoralis major muscle mass from 55,768 cardiovascular magnetic resonance examinations and combined this with body weight to derive a novel sarcopenic obesity index. Associations with cardiac remodeling phenotypes and adverse cardiovascular and mortality outcomes were tested in multivariable models. Genome-wide association analysis, colocalization, and polygenic risk score evaluation were performed for the sarcopenic obesity index. Transcriptomic profiling of skeletal muscle across 7 pathophysiological states assessed differential gene expression. RESULTS: A higher sarcopenic obesity index was associated with adverse cardiac remodeling, and with increased risk of incident heart failure (HR: 1.31; 95% CI: 1.16-1.49), cardiovascular death (HR: 1.51; 95% CI: 1.25-1.81), and all-cause mortality (HR: 1.37; 95% CI: 1.26-1.49). Genome-wide association analysis identified 16 loci for sarcopenic obesity. Loci included genes associated with heart failure and nonischemic cardiomyopathy, with colocalization implicating shared causal variants in heart failure. Transcriptomic profiling demonstrated that sarcopenic obesity loci were specifically modulated during muscle atrophy. Analyses identified ACVR2B, the target of bimagrumab, which is being tested with semaglutide to enhance fat loss while maintaining lean mass. CONCLUSIONS: These results establish sarcopenic obesity as a clinically meaningful cardiovascular risk phenotype and point to viable therapeutic targets.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Sanghvi, Nicholls, Kaplan, et al. Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology. J Am Coll Cardiol. 2026. PMID: 42383941. doi:10.1016/j.jacc.2026.05.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。